MA49249A - Nouveaux anticorps anti-hsa - Google Patents

Nouveaux anticorps anti-hsa

Info

Publication number
MA49249A
MA49249A MA049249A MA49249A MA49249A MA 49249 A MA49249 A MA 49249A MA 049249 A MA049249 A MA 049249A MA 49249 A MA49249 A MA 49249A MA 49249 A MA49249 A MA 49249A
Authority
MA
Morocco
Prior art keywords
new anti
hsa antibodies
hsa
antibodies
new
Prior art date
Application number
MA049249A
Other languages
English (en)
Inventor
Tessa Bieri
Tea Gunde
Christian Hess
Sebastian Meyer
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA49249A publication Critical patent/MA49249A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049249A 2017-06-05 2018-06-04 Nouveaux anticorps anti-hsa MA49249A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515293P 2017-06-05 2017-06-05
EP17195783 2017-10-10

Publications (1)

Publication Number Publication Date
MA49249A true MA49249A (fr) 2021-04-14

Family

ID=62555062

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049249A MA49249A (fr) 2017-06-05 2018-06-04 Nouveaux anticorps anti-hsa

Country Status (10)

Country Link
US (1) US11365240B2 (fr)
EP (1) EP3634997B8 (fr)
JP (1) JP7130678B2 (fr)
KR (1) KR102754842B1 (fr)
CN (1) CN110709418B (fr)
AU (1) AU2018280679B2 (fr)
CA (1) CA3064160A1 (fr)
ES (1) ES3015094T3 (fr)
IL (1) IL271127B2 (fr)
MA (1) MA49249A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065868C (fr) * 2017-06-05 2024-06-04 Numab Therapeutics AG Nouveau format d'anticorps multispecifique heterodimerique
CN113817686B (zh) * 2020-06-18 2023-11-14 上海医药工业研究院 一种杂交瘤细胞株及其分泌的单克隆抗体和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
CN116355092B (zh) * 2023-05-19 2023-07-21 广州明药科技有限公司 抗人血清白蛋白的纳米抗体及其应用
CN118667000A (zh) * 2024-06-28 2024-09-20 杭州旭科生物技术有限公司 抗hsa单克隆抗体及其应用
CN119331089B (zh) * 2024-12-19 2025-04-01 北京索莱宝科技有限公司 抗人白蛋白抗体7g7、抗体组合物及其应用
CN119320449B (zh) * 2024-12-19 2025-04-01 北京索莱宝科技有限公司 抗人白蛋白抗体5h11及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2010035012A1 (fr) 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
ES2655071T3 (es) * 2009-02-19 2018-02-16 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
MX2011008752A (es) 2009-02-19 2011-09-06 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas.
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US9803004B2 (en) * 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
EP4356927A3 (fr) * 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
CA2914829A1 (fr) * 2013-06-26 2014-12-31 Numab Therapeutics AG Structures d'anticorps
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
CA3065868C (fr) 2017-06-05 2024-06-04 Numab Therapeutics AG Nouveau format d'anticorps multispecifique heterodimerique
CA3074802A1 (fr) * 2017-10-10 2019-04-18 Numab Therapeutics AG Anticorps ciblant pdl1 et procedes d'utilisation associes
SG11202002982YA (en) * 2017-10-10 2020-04-29 Numab Therapeutics AG Multispecific antibody
US11578133B2 (en) * 2017-10-10 2023-02-14 Namab Therapeutics AG Antibodies targeting CD137 and methods of use thereof

Also Published As

Publication number Publication date
AU2018280679A1 (en) 2019-12-05
AU2018280679B2 (en) 2025-04-24
JP7130678B2 (ja) 2022-09-05
ES3015094T3 (en) 2025-04-29
EP3634997C0 (fr) 2025-02-26
EP3634997B1 (fr) 2025-02-26
IL271127A (en) 2020-01-30
US20200325214A1 (en) 2020-10-15
KR20200015505A (ko) 2020-02-12
EP3634997A1 (fr) 2020-04-15
CN110709418A (zh) 2020-01-17
JP2020522250A (ja) 2020-07-30
IL271127B2 (en) 2024-10-01
US11365240B2 (en) 2022-06-21
CN110709418B (zh) 2023-09-26
IL271127B1 (en) 2024-06-01
EP3634997B8 (fr) 2025-04-02
KR102754842B1 (ko) 2025-01-17
CA3064160A1 (fr) 2018-12-13

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
EP3498840A4 (fr) Anticorps anti-lag-3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
EP3423089A4 (fr) Anticorps anti-tigit
MA50352A (fr) Anticorps multispécifiques
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3334763A4 (fr) Nouveaux anticorps anti-pd-1
EP3596126A4 (fr) Nouveaux anticorps anti-trkb
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
MA49250A (fr) Nouveaux anticorps anti-cd3
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526251A4 (fr) Anticorps anti-p53
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3349794A4 (fr) Anticorps anti-cd115